ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20150011560A1
SERIAL NO

14364320

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant or FGFR3.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ASSISTANCE PUBLIQUE-HOPITAUX DE PARISHÔPITAL SAINT LOUIS 1 AVENUE CLAUDE VELLEFAUX PARIS 75010
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)3 RUE MICHEL ANGE 75016 PARIS FRANCE
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)101 RUE DE TOLBIAC PARIS 75013
UNIVERSITE PARIS DIDEROT - PARIS 775013 PARIS
UNIVERSITE PARIS DESCARTES75006 PARIS
IMAGINE5 PLACE DES ALLIÉS 68290 MASEVAUX-NIEDERBRUCK 68290

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Legeai-Mallet, Laurence Paris, FR 15 45

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation